Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
19
02
2020
revised:
21
03
2020
accepted:
18
05
2020
pubmed:
22
5
2020
medline:
26
11
2021
entrez:
22
5
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICI) may overcome cancer cells' ability to evade the immune system and proliferate. The long-term benefit of ICI in the metastatic setting led to evaluate neoadjuvant ICI approaches in several tumor types such as melanoma, non-small cell lung cancer, and breast and bladder cancer. We summarize the current evidence for the efficacy of neoadjuvant ICI in cancer and discuss several unresolved challenges, including the role of adjuvant treatment after neoadjuvant ICI, the efficacy in oncogenic addicted tumors, and standardizing pathologic assessment.
Identifiants
pubmed: 32434852
pii: 1078-0432.CCR-19-3255
doi: 10.1158/1078-0432.CCR-19-3255
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5068-5077Informations de copyright
©2020 American Association for Cancer Research.